Relay Therapeutics/$RLAY
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Relay Therapeutics
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
- Ticker
- $RLAY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 202
- Headquarters
- Cambridge, United States
- Website
- www.relaytx.com
RLAY Metrics
BasicAdvanced
$3.8B
-
-$1.57
1.70
-
Price and volume
Market cap
$3.8B
Beta
1.7
52-week high
$21.27
52-week low
$5.95
Average daily volume
2.7M
Financial strength
Current ratio
18.268
Quick ratio
17.93
Long term debt to equity
0.03
Total debt to equity
0.034
Profitability
EBITDA (TTM)
-308.224
Gross margin (TTM)
-2,497.55%
Net profit margin (TTM)
-2,763.64%
Operating margin (TTM)
-2,999.37%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-22.88%
Return on equity (TTM)
-36.77%
Valuation
Price to revenue (TTM)
306.956
Price to book
4.28
Price to tangible book (TTM)
4.28
Price to free cash flow (TTM)
-14.971
Free cash flow yield (TTM)
-6.68%
Free cash flow per share (TTM)
-1.165
Growth
Revenue change (TTM)
23.88%
Earnings per share change (TTM)
-18.31%
3-year revenue growth (CAGR)
122.31%
3-year earnings per share growth (CAGR)
-18.50%
What the Analysts think about RLAY
Analyst ratings (Buy, Hold, Sell) for Relay Therapeutics stock.
Analyst projections of the future price of Relay Therapeutics stock.
Bulls say / Bears say
At the recommended Phase 3 dose, an interim study reported median progression-free survival of 11.1 months for zovegalisib plus fulvestrant in heavily pre-treated patients. Relay is testing the combination in a Phase 3 trial, giving its lead programme a promising clinical signal to prove. (Relay Therapeutics)
Zovegalisib combined with Pfizer’s atirmociclib produced a 44% response rate in a heavily pre-treated breast-cancer group. Relay plans a Phase 3 study in earlier-line disease, which could open a larger treatment opportunity if the result holds up. (Relay Therapeutics)
In an early vascular-anomalies study, 60% of evaluable patients had a reduction in lesion volume by week 12, and nearly all reported symptom improvement. This offers zovegalisib a potential use beyond cancer, although the findings still need confirmation in larger studies. (Relay Therapeutics)
The encouraging zovegalisib results are interim, and Relay has not yet completed a large pivotal trial. The Phase 3 study must confirm that early efficacy and safety translate into a reliable benefit. (SEC)
Relay reported an $83.7 million quarterly loss and raised about $316 million through a share offering in May. Its cash is expected to last into 2029, but continued heavy spending and further fundraising could dilute shareholders. (Relay Therapeutics, SEC)
Zovegalisib faces established PI3K and AKT treatment options, including capivasertib, which is the active comparator in Relay’s Phase 3 trial. Even a positive trial may not secure uptake if its benefit or tolerability is not compelling against available alternatives. (Journal of Clinical Oncology)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
RLAY Financial Performance
Revenues and expenses
RLAY Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing RLAY
Fund name | Fund size | $RLAY weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.28% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.28% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.28% |
iShares Ageing Population$AGED | $953M | 0.24% |
iShares Ageing Population£AGES | $953M | 0.24% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.